‘Landmark’: New mRNA vaccine could prevent skin cancer from returning, companies say
Moderna and Merck said the personalised vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.smh.com.au — the content belongs to Sydney Morning Herald - World.
